Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126448143 | 12644814 | 3 | F | 20160824 | 20160811 | 20160830 | PER | US-PFIZER INC-2016382130 | PFIZER | 52.00 | YR | M | Y | 106.59000 | KG | 20160830 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126448143 | 12644814 | 1 | PS | GABAPENTIN. | GABAPENTIN | 1 | Oral | 300 MG, 4X/DAY (120 CT BOTTLE PER MONTH) | U | 20235 | 300 | MG | CAPSULE, HARD | QID | |||||
| 126448143 | 12644814 | 2 | SS | GABAPENTIN. | GABAPENTIN | 1 | U | 20235 | CAPSULE, HARD | ||||||||||
| 126448143 | 12644814 | 3 | SS | NAPROXEN. | NAPROXEN | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126448143 | 12644814 | 1 | Diabetic neuropathy |
| 126448143 | 12644814 | 2 | Neuropathy peripheral |
| 126448143 | 12644814 | 3 | Neuropathy peripheral |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126448143 | 12644814 | Drug ineffective for unapproved indication | |
| 126448143 | 12644814 | Intentional product misuse |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |